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ABSTRACT (250/250) 
Orthostatic hypotension (OH) is reported to be more prevalent particularly in patients with 
Dementia with Lewy bodies (DLB) because of the autonomic dysfunction, but prevalence of 
OH is not known in patients with Alzheimer Disease (AD). The aim of the present study was 
to determine whether OH can be used to distinguish DLB from AD. 38 patients with DLB, 88 
patients with AD and 521 patients without dementia, underwent Comprehensive Geriatric 
Assessment. OH were evaluated for the 1
st
 (OH1) and 3
rd
 (OH3) minutes, taking the data in 
supine position as the basis, by Head-Up-Tilt Test. Prevalence of OH1 was 43.2% in AD, 
44.7% in DLB and 17.9% in patients without dementia, and OH3 was 44.3% in AD, 47.4% in 
DLB and 17.9% in non-dementia group. The frequency of OH1 and OH3 was higher in the 
AD and DLB groups than in the patients without dementia (p<0.001), but there was no 
significant difference between DLB and AD in terms of OH (p>0.05). The percentage of 
asymptomatic patients with OH was 87.2% and 89.6% during 1
st
 and 3
rd
 minutes, 
respectively, and this percentage was similar in three groups (p>0.05, for each). There was no 
significant difference between the two dementia groups in terms of comorbidities, drugs and 
laboratory values (p>0.05). OH is more prevalent in patients with AD than controls and 
similar levels are observed in those with DLB. The prevalence of OH equally is greater with 
DLB or AD disease progression. Clinicians should be aware of OH and its related 
consequences in the management of the AD in older adults. 
Keywords: Alzheimer’s Disease, Dementia with Lewy bodies, Elderly, Orthostatic 
hypotension. 
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INTRODUCTION 
Autonomic dysfunction is common in patients with dementia, and Orthostatic hypotension 
(OH) is the second most-common autonomic dysfunction after urinary dysfunction [1,2].  The 
prevalence of OH increases with age, and it indicates an increased risk of dementia and 
cognitive decline [3]. Additionally, OH cannot only cause several negative health 
consequences including cardiovascular events, falls, fractures, progression of dementia, and 
mortality in older adults [3,4], but it can be considered as a marker or risk factor of clinical 
frailty, as well[5,6]. On the other hand, cognitive impairment is a common health problem in 
older adults, and the number of people with dementia is increase predominantly owing to a 
global ageing population. Moreover, patients with dementia are at high risk of developing 
OH, and the relationship between OH and dementia may be a consequence of multiple 
mechanism one of which is the recurrent transient brain hypoperfusion hypothesis [7].
 
Although, potential association between OH and cognitive impairment has been evaluated in 
several studies, OH is reported to be prevalent in patients with Dementia with Lewy bodies 
(DLB) [7,8]. 
DLB is the second most common dementia, after Alzheimer’s disease (AD), with a clinical 
prevalence of 15-42% of all dementia cases [9-11] and previous studies have demonstrated 
that prevalence of OH has been reported in 42-69% of patients with DLB [11,12].
 
Therefore, 
due to the high prevalence OH, it is accepted as one of the supportive clinical features of the 
disease together with other signs of autonomic dysfunction, such as constipation, and urinary 
incontinence [13].
 
Actually, autonomic dysfunctions are well-known, as a part of all the alfa-
syncleinopathies including Multiple System Atrophy (MSA), DLB and Parkinson's Disease 
(PD), because of the presence of Lewy bodies in brain regions such as the locus coeruleus 
[14,15].
 
However, despite the fact that OH, as a sign of autonomic dysfunction, might also 
help in differential diagnosis among dementia subtypes, it should be kept in mind that 
autonomic dysfunction is common in all forms of dementia [2,14],
 
and reported  prevalence of 
OH is between 33-42% in patients with AD whereas it is between 13-14% in healthy controls 
[11,12]. In AD, it has been reported that both generalized deficit in cholinergic function and 
involvement of subcortical structures, implicated in autonomic nervous system regulation, in 
the disease course may be led to autonomic dysfunction [1,2]. 
Until now, although the importance of OH for dementia practice is well known, there are no 
previous prospective studies of OH comparing the most common dementia subtypes in the 
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elderly, AD and DLB. For this reason, this study aimed to evaluate the presence and 
frequency of OH, measured by Head up Tilt Table (HUT), in elderly patients with AD or 
DLB and without dementia.  
PATIENTS AND METHODS 
Study design 
 A total of 647 older adults, who were admitted to one geriatric clinic between January 2016 
and June 2018, were included in this prospective observational study. Comprehensive 
Geriatric Assessment (CGA) including HUT was performed in those geriatric patients after 
obtaining their informed written consents. 
Inclusion Criteria 
Patients all over 65 years old who were admitted to the department of geriatrics for any reason 
and who had no exclusion criteria were included in this study. 
Exclusion Criteria 
Patients with severe anemia (<10 g/dL), severe metabolic acidosis, electrolyte imbalance, 
severe kidney or heart failure, hypotensive or septic shock, coma, gastrointestinal bleeding,  
severe mitral valve or aortic valve stenosis, tachycardia, severe proximal cerebral artery 
stenosis, severe coronary artery disease, prior stroke or myocardial infarction in the past 7 
days, lower extremity fractures, all of which are contraindications of HUT, were excluded [1].
 
In addition, patients with dementia except those with probable DLB or AD were also 
excluded. 647 patients were available for study analysis. 
Orthostatic Blood Pressure Measurement 
HUT Test was performed for the diagnosis of OH. The test was performed in the morning 
after the patients received their daily medications and patients were told not to smoke, drink 
caffeine, or exercise within 30 min prior to the test. HUT was performed by tilt Table 
(Gemesan1 Tilt TableG-71, Turkey). Monitoring over the course of HUT was applied by 
Biolight® BIOM69 (Australia) with a reusable adult arm cuff. After allowing the patients to 
rest in a silent room with temperature of 20– 24 0C for at least 10 min in a supine position, the 
tilt Table was rapidly and fluently raised up to an angle of 60–800. The data of monitoring at 
the 1
st
 (HUT1)  and 3
rd
 minutes (HUT3) were recorded.  The diagnosis of OH was made in the 
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event of 20 mmHg and higher decrease in systolic pressure and/or 10 mmHg and higher 
decrease in diastolic pressure during transition from the supine position to at least 60˚ head-up 
position during HUT [16,17]. According to this definition, orthostatic blood pressure at the 
1st and 3rd minutes were evaluated taking the data of supine position as the basis. 
Diagnosis of Alzheimer’s Disease (AD) and Dementia with Lewy Body (DLB) 
AD (probable) was diagnosed with National Institute on Aging-Alzheimer’s Association 
workgroup’s criteria [18] and DLB (36 of probable and 2 of possible) was diagnosed with 
Fourth consensus report of the DLB Consortium [13].
 
The assessment of dementia stages was 
classified according to the Clinical Dementia Rating (CDR) and all patients underwent cranial 
imaging. 
Ethical issues 
The study was conducted in conformity with the Declaration of Helsinki and was approved by 
the ethics committee of the School of Medicine, Dokuz Eylul University in Izmir, Turkey. All 
participating subjects gave their written informed consent. 
Comprehensive Geriatric Assessment (CGA)
 
[19] 
Demographic characteristics (age, gender, and years of education) were recorded. Patients 
were questioned in terms of recurrent falls (> 1 falls/year) and balance impairment within the 
past year. Patients with were interrogated for comorbidities. Laboratory data, which was 
performed routinely in geriatric population, was obtained. All participants were queried 
regarding the use of medication that could lead to OH. These medications include drugs that 
block angiotensin, calcium channel blockers, beta blockers, alpha blockers, diuretics, nitrates, 
antidepressants and antipsychotics. Basic and Instrumental Activities of Daily Living (ADL) 
were assessed by Barthel Index and Lawton-Brody Scale, respectively. Nutritional status was 
assessed using the Mini-Nutritional Assessment (MNA) score. Cognitive status was evaluated 
by Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (Scale).  
Statistical Analysis 
The participants were divided into three groups: AD, DLB and non-Dementia groups. All 
statistical analyzes were performed to compare three groups. Continuous variables were 
assessed as means and standard deviations and evaluated by Kolmogorov-Smirnov test for 
normal distribution. Normally distributed continuous variables were analyzed by paired 
sample t-test. In case of non-normal distribution, continuous variables were evaluated by 
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Mann Whitney U test. Differences between categorical variables were evaluated by Chi-
square and Fisher’s exact Chi-square tests. A probability <0.05 was considered as significant. 
All statistical analyses were carried out using SPSS 22.0 (SPSS Inc.). Binary logistic 
regression analysis was performed to assess covariate factors between binary groups (AD and 
no dementia group, DLB and no dementia group). The sample sizes were calculated as 72 for 
AD and 25 for DLB to ensure that the minimum required size necessary for comparing 
prevalence of OH was within 95% confidence interval and 5% within marginal failure. 
Additionally, the power of study was calculated as 99.6% for AD and 94.2% for DLB by the 
post-hoc power calculation. 
 
RESULTS 
Of 647 patients, 13.6% had AD and 5.8% DLB. There were more females than males in all 
groups. Prevalence of OH1 was 43.2% in AD, 44.7% in DLB and 17.9% in non-dementia 
group, and OH3 was 44.3% in AD, 47.4% in DLB and 17.9% in non-dementia group. There 
were no significant differences between the two dementia groups in terms of comorbidities, 
frail people, drugs and laboratory values (p>0.05). Gait and balance and up & go scores, 
Basic and Instrumental ADLs, Nutritional evaluation were worse in the AD and DLB group 
than in the non-dementia group. Prevalence of frailty was higher in the patients with dementia 
than in the patients without dementia (p<0.05). It was higher in both OH1 (50%) and OH3 
(49.5%) groups than in the non-OH group, too (p=0.004 and p=0.006, respectively). MMSE 
scores was not different between AD and DLB group (p>0.05). Patients’ characteristics are 
shown in table 1.  
While the prevalence OH, OH1 and OH3 was significantly higher in the AD and DLB groups 
than in the non-dementia group (p <0.001), they were similar in DLB and AD groups 
(p>0.05) (Figure 1). The percentage of asymptomatic patients with OH was 87.2% during 
HUT1 and 89.6% during HUT3 and this percentage was similar in three groups (P>0.05, for 
each). The significant relationship between AD and OH was maintained when adjusted for 
age, gender, balance and gait tests, ADLs, nutritional tests and drug usage (B:0.74 p<0.039 
for OH1 and B:0.85 p<0.019 for OH3). 
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In addition, the prevalence of OH increases with CDR scale in AD group (p<0.05), and there 
is no significant difference between AD and DLB groups in all three CDR stages (p>0.05) 
(Figure 2). 
 
 
 
DISCUSSION 
In this cross-sectional study, it was demonstrated that the prevalence of OH, determined by 
HUT, a gold standard method for diagnosis OH, in elderly patients with AD was similar to 
those with DLB. It was also demonstrated that this prevalence was greater with progression of 
AD. 
Presence of OH, a sign of autonomic dysfunction, might not only help in differential 
diagnosis among dementia subtypes, but it is also one of the supportive clinic criteria of DLB 
and crucial for the diagnosis of MSA [14,20].
 
On the other hand, since OH is independently 
associated with an increased risk of dementia and common in patients with dementia [7,21], 
early recognition and screening of OH are quite important to prevent for OH related 
complications such as, increase the risk of morbidity, institutionalization, and mortality in 
dementia practice [1]. As shown in our results, OH in patients with AD is similar to those 
with DLB (43.2%, 44.7% for OH1, and 44.3%, 47.4% for OH3, respectively) and higher than 
controls (17.9%). Furthermore, nearly 90% of these patients were asymptomatic during HUT. 
In the light of these results, it is clear that OH requires special attention in patients with AD, 
considering that it is a specific risk factor for falls in patients with dementia and may be a 
predictor of mortality in DLB patients [22]. Additionally, a recent study has demonstrated that 
OH is a common condition in frail older adults and it is well known that patients with 
dementia are more common to have frailty as shown our results [5,6]. 
Our results are generally consistent with the literature in contrast to several studies. The 
discrepancy from these studies might result from a variety of methods of OH diagnosis and 
small sample size. For example, a recent study reported that prevalence of OH is lower in AD 
than in DLB and PD Dementia and suggested that autonomic function tests, such as OH, 
might be useful in distinguishing DLB from AD [23], but OH was defined as a reduction in 
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systolic blood pressure of greater than 30 mm Hg in this study different from standard OH 
diagnosis
 
[16,17,24] and our study. Moreover, those with DLB and PDD will likely be taking 
antiparkinsonian drugs that are well known to cause OH and there is no information about 
this, or antihypertensive therapy, reported in the study [23,25].
 
The present study was able to 
assess all the factors affecting OH, since comorbidities, laboratory parameters and drugs were 
detailed. Therefore, to the best of our knowledge, it is the first study to evaluate clearly OH in 
patients with AD and DLB. On the other hand, given the fact that the prevalence of 
coexistence of AD and DLB was reported as 9% in a study, designed for neuropathological 
evaluation of mixed dementia [26], it should be kept in mind that some patients may have 
both AD and DLB clinics, and DLB, in these patients, may also be underdiagnosed. 
Indeed, it is not surprising that the frequency of OH in patients with AD is similar to those 
with DLB, due to following reasons: first, one of the most important factors for regulation of 
orthostatic blood pressure is hypothalamic–pituitary–adrenocortical (HPA) axis and suitable 
sympathetic response to postural changes. Previous studies have shown that activity of the 
HPA axis increases in patients with AD; thus, there are increased basal concentrations of 
cortisol in plasma, urine, and cerebrospinal fluid and decreased sensitivity of the HPA axis in 
these patients [27,28].
 
For example, one experimental study, by Brureau et al, demonstrated 
that accumulation of amyloid-β could lead to disturbance in the feedback of the HPA axis in a 
rodent model [28]. Also, an increased deterioration in HPA axis, basal sympathoneural 
activity and cardiovascular responsiveness have been repeatedly demonstrated in AD [27-29]; 
which can facilitate the development of OH. Second, AD reaches the insular cortex, part of 
autonomic function, at a ‘‘preclinical’’ stage according to Braak sequence and its infarction 
has caused both cardiac arrhythmias and cardiovascular mortality; thus, this may explain why 
OH and central autonomic cardio-regulatory dysfunctions can be developed in AD [30]. 
Third, involvement of several subcortical structures playing a role in autonomic nervous 
system regulation, such as the hypothalamus, locus coeruleus, cerebral neocortex, insular 
cortex and brainstem during the disease course were also associated with autonomic 
dysfunction [31,32]. The other mechanism may be the cholinergic vascular hypothesis in AD 
brain. In fact, loss of the cortical perivascular cholinergic nerve terminals, may contribute to 
the impairment of the observed reduction in cerebral blood flow in AD brain [1,30]. 
Additionally, there is much evidence that AD lead to functional and structural changes in 
large arteries, arterioles, and capillaries [33]. Therefore, those arteriolar dysfunctions can 
cause impairment in CBF autoregulation and develop OH. Based on these findings, it is likely 
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that OH and autonomic dysfunction are common in patients with AD, like DLB, and that AD 
may affect both cortex and subcortical structures in the brain at the beginning of the disease. 
For this reason, it should also be paid attention to OH and OH related consequences in the 
management of the patients with AD.   
One strength of this study is that orthostatic blood pressure was measured by HUT, while in 
previous studies it was measured by the active standing test (AST) [9-12]. According to 
diagnosis of OH, when HUT was used as the gold standard for comparison, AST had lower 
sensitivity, specificity, and positive predictive value in elderly patients [34]. OH determined 
by HUT is likely of higher clinical significance than by AST. Another strength is that all 
patients were evaluated by comprehensive geriatric assessment including comorbidities, 
laboratory parameters and detailed drugs history. Finally, healthy controls were used. The 
present study has some limitations.  First, the design of the study is cross-sectional. Second, 
the number of patients with dementia, especially DLB patients, is not enough to evaluate the 
comparison between different stages of dementia. Third, this study did not 
neuropathologically confirm the dementia diagnosis. 
In conclusion, OH in patients with AD is more prevalent than in controls but has a similar 
prevalence to those with DLB. The prevalence of OH increases with disease progression, even 
if these patients are asymptomatic during test. Clinicians should be aware of OH and its 
related consequences in the management of the AD in older adults 
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Table 1. PATIENTS CHARACTERISTICS 
ACE: Angiotensin-Converting Enzyme Inhibitors; AcHEIs : Acetylcholinesterase Inhibitors; ADL: Activities of 
Daily Living; ARB: Angiotensin II Receptor Blockers; BB: Beta-Blockers; CCB: Calcium Channel Blockers; 
eGFR: estimated Glomerular Filtration Rate; MDRD: Modification of Diet in Renal Disease; MMSE: Mini-
Mental State Examination; MNA-sf: Mini-Nutritional Assessment (short form); TSH: Thyroid Stimulating 
Hormone 
P1: Comprasions between AD and No dementia groups; P2: Comprasions between DLB and No dementia 
groups; P3: Comprasions between AD and DLB groups 
 
 
 AD 
n=88 
DLB 
n=38 
No dementia 
n=521 
p1 p2 p3 
Female Sex (%) 60.2 60.5 71.4 0.035 0.158 0.975 
Age 77.41±8.70 77.92±2.33 75.40±25.22 0.001 0.004 0.911 
Recurrent falls (%) 33.0 55.3 30.4 0.822 0.007 0.019 
Balance disorder (%) 39.1 60.5 49.3 0.077 0.179 0.027 
COMORBIDITIES (%) 
Hypertension 62.5 60.5 68.7 0.248 0.299 0.834 
Ischemic Heart Disease 10.2 21.1 20.5 0.023 0.944 0.103 
Heart Failure 6.8 7.9 7.9 0.732 0.998 0.829 
Peripheral Artery Disease 3.4 2.3 6.3 0.282 0.109 0.249 
Cerebrovascular Events 2.3 5.3 5.8 0.175 0.897 0.380 
Diabetes Mellitus 19.3 34.2 29.6 0.048 0.550 0.072 
Hyperlipidemia 13.6 21.1 20.3 0.141 0.921 0.296 
Depression 40.9 52.6 42.4 0.791 0.215 0.224 
Frail (by FRIED criteria) 51.1 75.0 33.1 0.016 <0.001 0.052 
LABORATORY VALUES 
Hemoglobin (g/dL) 12.71±1.51 12.54±1.23 12.75±1.41 0.555 0.395 0.733 
TSH (mIU/L) 1.55±1.43 1.42±0.77 1.74±2.29 0.537 0.724 0.933 
Vitamin B12 (pg/ml) 542.34±396.87 474.44±366.46 432.20±328.71 0.008 0.276 0.459 
Vitamin D (ng/ml) 20.79±9.99 26.02±23.09 23.03±12.46 0.172 0.610 0.203 
COMPREHENSIVE GERIATRIC ASSESSMENT 
MMSE 14.31±5.95 15.50±4.88 25.35±4.29 <0.001 <0.001 0.362 
POMA-Balance 13.31±3.04 11.42±4.60 13.93±2.72 0.021 <0.001 0.021 
POMA-Gait 10.18±1.84 8.92±3.14 10.58±2.06 0.007 <0.001 0.049 
POMA-Total 23.51±4.60 20.37±7.50 24.47±4.45 0.007 <0.001 0.026 
Up&Go  18.87±9.91 25.84±23.73 14.62±8.72 <0.001 <0.001 0.214 
Basic ADL 81.47±17.05 75.50±17.90 91.37±10.01 <0.001 <0.001 0.061 
Instrumental ADL 8.22±5.66 9.13±5.90 18.71±4.91 <0.001 <0.001 0.417 
MNA-sf score 10.91±2.16 9.73±3.04 12.29±2.03 <0.001 <0.001 0.062 
DRUG CLASS (%) 
ARB 26.1 18.4 37.2 0.044 0.019 0.351 
ACEI 13.6 13.2 15.2 0.710 0.735 0.942 
BB 25.0 21.1 30.9 0.264 0.199 0.633 
CCB 28.4 26.3 25.3 0.542 0.878 0.810 
Diuretics 31.8 28.9 37.8 0.312 0.292 0.749 
Alfa blockers 9.1 7.9 7.9 0.697 0.998 0.827 
Nitrats 4.5 7.9 3.8 0.753 0.226 0.451 
Antridepressants 53.4 47.4 32.1 <0.001 0.051 0.533 
Antipsychotics 13.6 15.8 3.1 <0.001 <0.001 0.751 
AcHEIs 92.0 92.1    0.870 
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Figure Legends: 
Figure 1: Study Design 
 
Figure 2: Prevalence of Orthostatic Hypotension in The Study Population 
AH: Alzheimer Disease; DLB: Dementia of Lewy Body; OH1: Orthostatic Hypotension within 1
st
 minute, 
OH3: Orthostatic Hypotension within 3
rd
 minutes 
 
Figure 3: Prevalence of Orthostatic Hypotension in patients with AD According to CDR 
AH: Alzheimer Disease; CDR: Clinical Deteriorating Scale; OH1: Orthostatic Hypotension within 1
st
 minute, 
OH3: Orthostatic Hypotension within 3
rd
 minutes 
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HIGHLIGHTS 
 
 OH is common in dementia with Lewy body as well as AD. 
 
 OH is more prevalent in patients with AD than in healthy controls. 
 
 OH should be taken into consideration in the follow-up of patients with AD as same as in DLB 
patients. 
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